A few months ago, a 44-year-old patient named Marcus in Austin called his prescriber's office after his first PT-141 injection. He'd drawn up 2 mg because "that's what the forums said." Within 30 minutes he was fighting waves of nausea so severe he couldn't leave the bathroom, let alone do anything romantic. His prescriber, reviewing the chart the next morning, put it bluntly: "You skipped the tolerance dose. That's the single most common mistake I see with this peptide."
Marcus's experience is not unusual. PT-141 (bremelanotide) works, and the clinical data backs that up, but the dosing details matter more than with most peptides people self-administer. Here's what the evidence and current clinical practice actually look like.
The Basics: What PT-141 Is and Isn't
Bremelanotide is a synthetic cyclic heptapeptide, a melanocortin receptor agonist with primary activity at MC4R in the central nervous system. The mechanism is important because it's completely different from PDE5 inhibitors like sildenafil or tadalafil. Those drugs work on blood vessels. PT-141 works in the brain. That distinction shapes everything about how and when you dose it.
The branded version, Vyleesi, is FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women. Compounded PT-141 is used off-label in men with erectile or libido concerns, in post-menopausal women, and sometimes in combination products. None of that off-label use carries FDA approval.
The FDA-Approved Dose (Vyleesi)
For premenopausal women with HSDD, the label is straightforward:
- 1.75 mg subcutaneously via prefilled autoinjector
- At least 45 minutes before anticipated sexual activity
- No more than 1 dose per 24 hours
- Cap of 8 doses per month
The Kingsberg SA et al. 2019 RECONNECT trials (two randomized, placebo-controlled phase 3 studies) established both efficacy and safety at this dose. That 8-dose monthly ceiling isn't arbitrary. It reflects cumulative cardiovascular effects (transient blood pressure spikes) and the risk of focal hyperpigmentation with chronic use.
Starting Low: Why 0.5 mg Exists
Here's the thing about PT-141 that catches people off guard: nausea is dose-dependent and hits hard when it hits. The standard compounded starting dose is 0.5 mg subcutaneously, specifically to gauge tolerance before scaling up.
Get provider-reviewed GLP-1 therapy
Side effects are manageable with the right support. A licensed provider can adjust your dose when you need it.
Start Free Assessment →Most prescribers step patients from 0.5 mg to 1.25 mg, then to 1.75 or 2 mg based on response and side effects. Skipping this (like Marcus did) is how you end up spending an evening hovering over a toilet instead of having the evening you planned.
The typical working range for most adults lands between 1.25 and 2 mg subQ. Some men, particularly those with higher body weight, use up to 2 mg under prescriber supervision. Timing stays consistent: inject 45 to 60 minutes before anticipated activity.
Intranasal: Why It Lost and What to Know If You're Still Considering It
Earlier clinical development actually explored bremelanotide as an intranasal spray. It was faster to onset (15 to 30 minutes versus 45 to 60 for subQ) and more convenient. So why did the FDA-approved product end up as an injection?
Blood pressure. The intranasal route produced more pronounced transient BP elevations, and that signal was enough to redirect development toward subcutaneous delivery.
Compounded intranasal PT-141 preparations still circulate. If you're considering one, a few realities:
- Intranasal bioavailability differs from subcutaneous. You cannot do a milligram-for-milligram conversion and expect equivalent results.
- The BP concern isn't theoretical. It showed up in clinical trials.
- Stability profiles differ. Nasal preparations degrade differently than reconstituted subQ vials.
The boring truth is that subcutaneous injection is the route with the most safety data behind it. If you want to go intranasal anyway, have a specific conversation with your prescriber about cardiovascular risk first.
Reconstitution Math (Don't Guess)
Getting this wrong is like eyeballing a recipe for bread. Close enough isn't actually close enough when you're injecting a peptide.
10 mg vial + 1 mL bacteriostatic water = 10 mg/mL (1 mg per 0.1 mL)
Using a U-100 insulin syringe (where 1 unit = 0.01 mL):
- 0.5 mg = 5 units
- 1 mg = 10 units
- 1.25 mg = 12.5 units (split the marks)
- 1.75 mg = 17.5 units
- 2 mg = 20 units
10 mg vial + 2 mL bacteriostatic water = 5 mg/mL (0.5 mg per 0.1 mL)
- 0.5 mg = 10 units
- 1 mg = 20 units
- 1.75 mg = 35 units
- 2 mg = 40 units
The more dilute reconstitution is easier to work with at the lower end of the dose range, especially when you're starting at 0.5 mg. Larger tick marks, less squinting.
Injection Technique, Timing, and Storage
Sites: Lower abdomen (stay at least two inches from the navel) or outer thigh. Rotate between sites.
Technique: Pinch the skin, insert a 29 to 31 gauge insulin needle at 45 to 90 degrees, push the plunger slowly, withdraw, light pressure with clean gauze. Nothing exotic.
Onset: 45 to 60 minutes subcutaneously. Individual variation exists, but don't re-dose because you feel nothing at the 30-minute mark. That's how people double up and regret it.
Duration: Clinically meaningful effects typically persist for several hours. Bremelanotide's plasma elimination half-life is roughly 2.7 hours, but the subjective effects extend beyond that based on receptor-level pharmacology (Pfaus J et al., Journal of Sexual Medicine, 2007).
Storage: Keep unreconstituted vials refrigerated at 2 to 8°C. Once reconstituted with bacteriostatic water, refrigerate and use within approximately 28 days.
Population-Specific Notes
Men (off-label): The common compounded dose is 1.5 to 2 mg subQ, 45 to 60 minutes before activity. Start at 0.5 to 1 mg. This use is not FDA-approved but is well-established in compounding practice. Clayton AH et al. (Womens Health, 2016) studied bremelanotide in women, and the male evidence base relies more heavily on prescriber experience and smaller studies.
Post-menopausal women (off-label): Vyleesi's approval covers premenopausal women only. Off-label use in post-menopausal women follows similar dosing, but cardiovascular risk needs individual assessment. Estrogen status, baseline blood pressure, existing medications: all of it matters.
Combination products: PT-141 is sometimes compounded alongside low-dose tadalafil or oxytocin. If you're using a combination preparation, the dosing of each component should be governed by the specific formulation and your prescriber's protocol. Don't freelance with stacking.
What Not to Do
I'll be direct about the most common dosing mistakes because they keep showing up:
- Dosing more than once in 24 hours. No safety data supports this. Don't chase a stronger effect with a second injection the same day.
- Exceeding roughly 8 doses per month. The monthly cap exists because chronic high-frequency use is linked to focal hyperpigmentation, and transient BP elevations accumulate in ways that aren't fully characterized with frequent dosing.
- Stacking with vasoactive substances (poppers, other vasodilators, high-dose PDE5 inhibitors) without prescriber awareness. The BP profile of PT-141 interacts unpredictably with substances that also push blood pressure around.
- Ignoring existing cardiovascular risk factors. If you have uncontrolled hypertension, this peptide needs extra scrutiny before use.
Citations
Kingsberg SA et al. Bremelanotide for the treatment of HSDD: two randomized phase 3 trials (RECONNECT). Obstetrics and Gynecology. 2019.
Clayton AH et al. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized placebo-controlled trial. Womens Health (Lond). 2016.
Pfaus J et al. Bremelanotide: an overview of preclinical CNS effects on female sexual function. Journal of Sexual Medicine. 2007.
FAQ
What is the starting dose for PT-141?
0.5 mg subcutaneously for first-time users. This is a tolerance assessment dose, not a therapeutic target.
What is the standard PT-141 dose?
1.25 to 2 mg subQ for most adults. The FDA-approved Vyleesi label specifies 1.75 mg for premenopausal women with HSDD.
How often can I dose PT-141?
No more than once per 24 hours, with a conservative monthly cap of approximately 8 doses.
Can I use PT-141 daily?
No. Daily use is not supported by safety data. The intended pattern is spaced, as-needed dosing before anticipated sexual activity.
Is intranasal PT-141 better than subcutaneous?
Subcutaneous is the FDA-approved route and carries the most safety data. Intranasal compounded preparations exist but come with a more pronounced blood pressure signal from clinical development.
How do I reconstitute a 10 mg vial?
Add 1 mL or 2 mL of bacteriostatic water depending on your desired concentration. At 1 mL, you get 10 mg/mL. At 2 mL, you get 5 mg/mL (easier for precise low-end dosing). See the reconstitution table above.
How should I store reconstituted PT-141?
Refrigerate at 2 to 8°C. Use within approximately 28 days of reconstitution with bacteriostatic water.
Internal Links
- Hub: PT-141 overview
- Pillar: Peptide therapy overview
- Product: PT-141 product page
- Sibling: PT-141 side effects
- Sibling: PT-141 nasal vs injection
- Sibling: PT-141 onset and duration
---
Disclaimer: Vyleesi (bremelanotide) is FDA-approved for HSDD in premenopausal women. Compounded PT-141 used in other populations is off-label and not FDA-approved. Compounded PT-141 is prepared for individual patients through licensed compounding pharmacies based on prescriber clinical judgment. This article is educational and is not medical advice. Individual results vary.